Spencer Streit, D.O., Joins The Eugene M. and Christine E. Lynn Cancer Institute

Overview

Spencer Streit, D.O., a board-certified medical oncologist and hematologist, has joined the Eugene M. and Christine E. Lynn Cancer Institute.

Background

The addition of Dr. Streit to the Lynn Cancer Institute enhances the multidisciplinary approach to cancer care.

Data Highlights

No numerical or trial data is provided in the source material.

Key Findings

• Dr. Streit has a special interest in gastrointestinal cancers.
• He completed a hematology-oncology fellowship at Memorial Healthcare System, serving as chief fellow.
• Dr. Streit has contributed to research on gastric adenocarcinoma and targeted therapies.
• He is a member of several professional organizations, including ASCO and ASH.
• Dr. Streit emphasizes compassionate, patient-centered care throughout the cancer journey.

Clinical Implications

Dr. Streit's expertise in gastrointestinal cancers supports comprehensive cancer care.

Conclusion

Dr. Streit has joined the Lynn Cancer Institute.

Related Resources & Content

1. The ASCO Post, 2020 -- Martin F. Dietrich, MD, PhD, Joins Florida Cancer Institute
2. The ASCO Post, 2023 -- New Roles at St. Louis Siteman Cancer Center
3. The ASCO Post, 2023 -- Northwell Cancer Institute Welcomes New Chief of Hematologic Malignancies
4. the asco post — Brendon Stiles, MD, Named Chief of Thoracic Surgery & Surgical Oncology at Montefiore and Albert Einstein
5. Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer | New England Journal of Medicine
6. ‘Triple-Punch’ Combo Therapy Slows Progressions of Some Metastatic Colorectal Cancers - ASCO
7. ESMO Congress 2025 - Daily Reporter
8. Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update | Journal of Clinical Oncology
9. 2026 NCCN Clinical Practice Guidelines in Oncology®: Key Updates Across Tumor Types - The ASCO Post
10. Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: Primary results from the phase IIIb TOURMALINE study - Journal of Hepatology
11. https://www.oregon.gov/oha/HPA/DSI-HERC/MembersOnly/7.1d%20NCCN%202.2025%20pancreatic.pdf